53764-72-0

Usage

Uses

Used in Pharmaceutical Manufacturing:
4-Hydroxy-2-pyridinecarboxylic acid ethyl ester is used as an intermediate in the synthesis of various drugs and biologically active compounds. Its unique chemical structure allows it to be a key component in the development of new pharmaceuticals with diverse therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Hydroxy-2-pyridinecarboxylic acid ethyl ester is utilized as a precursor in the production of various agrochemicals. Its versatility in chemical reactions enables the creation of compounds that can be used in crop protection and other agricultural applications.
Used in Organic Synthesis:
4-Hydroxy-2-pyridinecarboxylic acid ethyl ester is employed as a versatile building block in organic synthesis. Its reactivity and functional groups make it suitable for the preparation of a wide range of organic compounds, including those with potential applications in materials science, pharmaceuticals, and other industries.
Used in Antioxidant and Anti-Inflammatory Agents Development:
Due to its antioxidant and anti-inflammatory properties, 4-Hydroxy-2-pyridinecarboxylic acid ethyl ester is used as a potential candidate for the development of therapeutic agents. Its ability to modulate biological processes and protect against oxidative stress and inflammation makes it a valuable component in the formulation of new treatments for various diseases and conditions.

InChI:InChI=1/C8H9NO3/c1-2-12-8(11)7-5-6(10)3-4-9-7/h3-5H,2H2,1H3,(H,9,10)

Upstream product

• 22468-26-4 4-hydroxypyridine-2-carboxylic acid 
• 64-17-5 ethanol 
• 475057-86-4 4-Hydroxy-2-pyridinecarbonitrile 
• 36057-44-0 2-cyano-4-methoxylpyridine 

Downstream Products

• 125545-98-4 ethyl 2SR-4-oxo-N-(t-butoxycarbonyl)piperidine-2-carboxylate 
• 129919-97-7 ethyl 4-hydroxy-N-(tert-butoxycarbonyl)piperidine-2-carboxylate 
• 153710-85-1 4-Hydroxy-piperidine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Drug efflux pump inhibitor

A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH═CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

4-(Tetrazolylalkyl)piperidine-2-carboxylic Acids. Potent and Selective N-Methyl-D-aspartic Acid Receptor Antagonists with a Short Duration of Action

We have prepared a series of cis-4-(tetrazolylalkyl)piperidine-2-carboxylic acids as potent and selective N- methyl-D-aspartic acid (NMDA) receptor antagonists.NMDA antagonists may prove to be useful therapeutic agents, for instance, as anticonvulsants, in the treatment of neurodegenerative disorders such as Alzheimer's disease and in the prevention of neuronal damage that occurs during cerebral ischemia.The compounds prepared were evaluated in vitro in both receptor binding assays (CGS-19755, AMPA, and kainic acid) and in a cortical-wedge preparation (versus NMDA, quisqualic acid, and kainic acid) to determine affinity, potency, and selectivity.The new amino acids were also evaluated in vivo for their ability to block NMDA-induced convulsions in neonatal rats and NMDA-induced lethality in mice.The most potent compound of this series, 15 (LY233053), selectively displaced CGS-19755 binding with an IC50 of 107 +/- 7 nM and selectively antagonized responses due to NMDA in a cortical-wedge preparation with an IC50 of 4.2 +/- 0.4 μm.Compound 15 blocked both NMDA-induced convulsions in neonatal rats (minimum effective dose (MED) = 20 mg/kg ip) and NMDA-induced lethality in mice (MED = 5 mg/kg ip).This is the first example of an NMDA receptor antagonist that incorporates a tetrazole moiety as an ω-acid bioisostere.These amino acid antagonists are also unique from their phosphonic acid counterparts in that they have a shorter duration of action in vivo.For the treatment of acute disorders such as stroke, where an NMDA antagonist would be administered parenterally, the shorter duration of action may be beneficial, e.g., allowing for better dosage control.The combination of potent NMDA receptor antagonism and a short duration of action may make these compounds useful therapeutic agents in the treatment of a variety of neurological disorders.